MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Oncology Therapeutics, Inc. - Common Stock (NQ:BBOT)

8.470 -0.350 (-3.97%)
Streaming Delayed Price Updated: 11:38 AM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 83,119
Open 8.800
Bid (Size) 8.460 (100)
Ask (Size) 8.470 (100)
Prev. Close 8.820
Today's Range 8.400 - 8.810
52wk Range 7.000 - 14.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Which stocks are gapping on Wednesday? ↗
Via Chartmill
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
-31.1%
-31.1%
1 Month
+9.6%
+9.6%
3 Month
-7.7%
-7.7%
6 Month
-26.4%
-26.4%
1 Year
-31.9%
-31.9%

More News

Read More
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
Via The Motley Fool
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BBOT to Participate in Upcoming Investor Healthcare Conferences
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire
News headline image
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From TheRas, Inc. (d/b/a BBOT)
Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Oncology Therapeutics, Inc. - Common Stock publicly traded?
Yes, BridgeBio Oncology Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does BridgeBio Oncology Therapeutics, Inc. - Common Stock trade on?
BridgeBio Oncology Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock?
The ticker symbol for BridgeBio Oncology Therapeutics, Inc. - Common Stock is BBOT on the Nasdaq Stock Market
What is the current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock?
The current price of BridgeBio Oncology Therapeutics, Inc. - Common Stock is 8.470
When was BridgeBio Oncology Therapeutics, Inc. - Common Stock last traded?
The last trade of BridgeBio Oncology Therapeutics, Inc. - Common Stock was at 07/15/26 11:38 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story